<p>This invention relates to the use of specific dosing regimens of telaprevir in combination with peg-IFN and RBV in the treatment of HCV patients, wherein the treatment comprises (a) a lead-in phase of administering to the subject pegylated interferon and ribavirin, and (b) a treatment phase of administering to the subject a combination of telaprevir, pegylated interferon and ribavirin.</p>
申请公布号
WO2009150194(A1)
申请公布日期
2009.12.17
申请号
WO2009EP57222
申请日期
2009.06.10
申请人
JANSSEN PHARMACEUTICA NV;BEUMONT, MARIA GLORIA;HERDINIUS, STEFAN, RIKARD;PICCHIO, GASTON, RAFAEL;POLO, RAMON
发明人
BEUMONT, MARIA GLORIA;HERDINIUS, STEFAN, RIKARD;PICCHIO, GASTON, RAFAEL;POLO, RAMON